1
|
Thal DR, Koelsch H, Papassotiropoulos A, Saido TC, Griffin ST, Dooren T, Leuven F, Ghebremedhin E. O2‐03‐03: Phenotypic and genetic subclassification of Alzheimer's disease. Alzheimers Dement 2009. [DOI: 10.1016/j.jalz.2009.05.336] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
2
|
Merchiers P, Dooren T, Van der Auwera I, Abulrob A, Lauwereys M, Roland B, Borghraef P, Decruy T, Lox M, Hoogenboom HR, Wera S, Stanimirovic D, Haard H, Leuven F. P4–245: Nanobodies™ targeting amyloid beta as potential therapeutics for Alzheimer's disease. Alzheimers Dement 2006. [DOI: 10.1016/j.jalz.2006.05.1985] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
| | - Tom Dooren
- Experimental Genetics GroupDept. Human GeneticsKULeuvenB-3000LeuvenBelgium
| | | | | | | | | | - Peter Borghraef
- Experimental Genetics GroupDept. Human GeneticsKULeuvenB-3000LeuvenBelgium
| | | | | | | | | | | | | | - Fred Leuven
- Experimental Genetics GroupDept. Human GeneticsKULeuvenB-3000LeuvenBelgium
| |
Collapse
|